NEW YORK – March 30, 2023** — Anavex Life Sciences has announced encouraging findings from its 48-week Phase 2 extension study
evaluating ANAVEX®2-73 (blarcamesine) in patients suffering from Parkinson’s
disease dementia. The results showed significant clinical benefits, achieving both primary and secondary endpoints.
The clinical-stage biopharmaceutical company, Anavex Life Sciences, focuses on developing innovative treatments for
neurodegenerative and neurodevelopmental disorders. ANAVEX®2-73, a sigma-1
receptor activator, demonstrated consistent improvements in patients’ clinical
symptoms over the 48-week study period.
The study assessed multiple efficacy endpoints, including the Movement Disorder Society-Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS), REM Sleep Behavior Disorder
Screening Questionnaire (RBDSQ), and Montreal Cognitive Assessment (MoCA).
Patients showed improved performance across all these measures while on
ANAVEX®2-73 treatment.
Dr. Christopher U Missling, President & CEO of Anavex, stated, “These findings highlight the
potential of ANAVEX®2-73 to address the urgent unmet needs in Parkinson’s
disease treatment.” He emphasized the drug’s promise in slowing and possibly
reversing the debilitating symptoms of the disease.
Anavex plans to proceed with a pivotal trial to further validate these positive outcomes.
The company has also secured a research grant from the Michael J. Fox
Foundation to support an imaging-focused Parkinson’s disease clinical trial.
This grant follows a previous award that funded a preclinical study, further
establishing ANAVEX®2-73 as a potentially disease-modifying treatment for Parkinson’s disease.
Parkinson’s disease affects approximately one million individuals in the United States and over ten
million worldwide. Current treatments primarily manage symptoms without halting
disease progression. The promising results from Anavex offer a glimpse of hope
for more effective, long-term solutions. Refer to this article for related information.
For more detailed information, visit [Anavex Life Sciences’ website](http://www.anavex.com).
Find more information about Anavex on https://www.nasdaq.com/market-activity/stocks/avxl